-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5173 Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) InitiativeClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research—Myeloid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Research, epidemiology, Clinical Research
Monday, December 11, 2023, 6:00 PM-8:00 PM

Pinkal Desai, MD, MPH1, Jacqueline S. Garcia, MD2, Joshua F. Zeidner, MD3, Sameem Abedin, MD4, Ofir Wolach5*, Pankit Vachhani, MD6, Yakir Moshe, MD, PhD7*, Daniel A. Pollyea, MD8*, Catherine Lai, MD9, Thomas W LeBlanc, MD10, Marin Xavier, MD11, Boaz Nachmias, MD12*, Evan C. Chen, MD13, Srilakshmi Bathini6, Inderpreet Bhatti14*, Cat N. Bui, PharmD, PhD15*, Annie Guérin, MS16*, Rebecca Burne17*, Esprit Ma, MPH18*, Moshe Grunspan19*, Neta Frankel19* and Aaron D. Goldberg, MD, PhD20

1Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY
2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
4Medical College of Wisconsin, Milwaukee, WI
5Rabin Medical Center, Petah Tikva, Israel
6O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
7Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
8University of Colorado School of Medicine, Aurora, CO
9Abramson Cancer Center, Georgetown University Hospital, Washington, DC
10Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
11Scripps Health, San Diego, CA
12Hebrew University, Jerusalem, Israel
13Dana Farber Cancer Institute, Boston, MA
14Scripps MD Anderson, San Diego, CA
15AbbVie Inc, North Chicago, IL
16Analysis Group, Inc, Montreal, Canada
17Analysis Group Inc, Montreal, Canada
18Genentech, Inc., South San Francisco, CA
19AbbVie Inc, Hod Hasharon, Israel
20Memorial Sloan Kettering Cancer Center, New York City, NY

Introduction: The BCL-2 inhibitor VEN is approved in combination with hypomethylating agents or low-dose cytarabine for adults with ND AML. The ARC Initiative is a multicenter chart review study of adult pts with AML. This abstract presents real-world clinical outcomes and hospitalizations among ND AML VEN treated pts ineligible for intensive chemotherapy (IC) and their matched controls.

Methods: This multicenter chart review study included adult pts (≥18 years) with ND AML who received VEN in combination with HMA on or after April 2016, or non-VEN regimens on or after May 2015, from 15 international academic sites (US: 11; Israel: 4). Pts ineligible for IC (i.e., ≥75 years or ≥1 comorbidity based on the Ferrara criteria) and treated with VEN (VEN cohort) were matched 1:1 to control pts who received non-VEN-based regimens (CON cohort). Pts were matched based on age (<60, 60-74, ≥75 years) and European LeukemiaNet (ELN 2017) risk. All analyses are based on the May 2023 data cutoff; data collection is ongoing. Clinical outcomes include composite complete remission (CRc; i.e., CR, CR with partial hematologic recovery [CRh], or CR with incomplete marrow recovery [CRi]) and overall survival (OS; assessed using Kaplan-Meier analysis). Hospitalizations were assessed overall and among pts who achieved CRc. Results were separately reported overall and among the respective subsets of VEN pts matched to CON pts treated with high-intensity regimens (CON-H) or low-intensity regimens (CON-L).

Results: A total of 142 IC-ineligible VEN pts and 142 matched CON pts were included in the analysis, including 80 VEN pts matched to CON-H pts (56.3%) and 62 VEN pts matched to CON-L pts (43.7%) (Table 1). Overall, VEN pts received VEN-azacitidine (75.4%) or VEN-decitabine (24.6%). A total of 68.3% of all pts were classified as ELN adverse risk, and 24.6% of VEN pts and 20.4% of CON pts were classified as Eastern Cooperative Oncology Group (ECOG) Grade ³2. Among pts with genetic mutations tested (96.5% of VEN pts and 94.4% of CON pts), 22.6% of VEN pts and 14.2% of CON pts had TP53 mutations and 21.9% and 19.4%, respectively, had IDH1/2 mutations.

VEN pts had a mean of 11.6 months of follow-up, and CON pts had a mean of 15.0 months of follow-up. VEN pts were significantly more likely to achieve CRc than CON pts (64.7% vs 44.3%, p=0.001). This difference was more pronounced for VEN pts matched to CON-L pts (62.1% vs 18.0%, p<0.001). The 6-month OS rates were not statistically different between VEN pts and matched CON pts (74.7% vs 67.6%; p=0.20), despite the majority of CON pts receiving high-intensity regimens, but improved among VEN pts matched to CON-L pts (73.5% vs 55.3%; p<0.05).

VEN pts had fewer days of hospitalization per pt per month (PPPM; mean 6.3 days vs 8.9 days, p=0.045) and shorter mean duration of hospitalization (13.7 days vs 18.2 days, p<0.001) compared with CON pts. A larger difference was seen in the amount of time (days) (6.5 vs 10.5 PPPM, p=0.006) and mean length of hospital stay (13.9 vs 22.4 days, p<0.001) for VEN pts matched to CON-H pts. Among pts with ≥1 all-cause hospitalization, 69.2% of VEN pts and 74.8% of CON pts were hospitalized for treatment administration (p=0.42).

Among pts who achieved CRc, VEN pts had fewer days of hospitalization PPPM than CON pts (mean 4.3 days vs 6.8 days, p=0.002). This difference was more pronounced for VEN pts compared to CON-H pts (4.3 days vs 7.7 days, p=0.001). Mean duration of hospitalization was also shorter for VEN vs CON pts (13.6 days vs 20.4 days, p<0.001). Both VEN and CON pts experienced more hospitalizations before CRc was achieved, with statistically fewer hospitalizations for VEN pts compared with CON pts (days of hospitalization PPPM: 10.1 vs 17.4, p=0.001; duration of hospitalization: 16.4 vs 28.2, p<0.001). In the 60 days after CRc was achieved, VEN pts still had fewer days of hospitalization PPPM than CON pts (1.4 vs 5.2, p<0.001).

Conclusions: Pts with ND AML who were ineligible for IC and received VEN had significantly higher rates of CRc than matched pts who received non-VEN-based regimens. Although pts treated with VEN-based regimens achieved similar rates of CRc compared to matched control pts treated with high-intensity therapy, pts treated with VEN-based regimens required a significantly lower burden of hospitalizations compared with matched pts on non-VEN-based regimens.

Disclosures: Desai: Janssen Research & Development: Research Funding; BMS: Consultancy, Other: Advisory role; Servier: Consultancy, Other: Advisory role; Abbvie: Consultancy, Other: Advisory role; Janssen Pharmaceuticals: Current Employment. Garcia: AbbVie: Consultancy, Research Funding; AstraZeneca: Research Funding; Pfizer: Research Funding; Prelude: Research Funding; New Wave: Research Funding; Servier: Consultancy; Gilead: Consultancy; Genentech: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy; Astellas: Consultancy. Zeidner: Arog: Research Funding; Daiichi Sankyo: Honoraria; Sumitomo Dainippon Pharma: Research Funding; Stemline: Research Funding; Shattuck Labs: Honoraria, Research Funding; Servier: Consultancy, Honoraria; Astex: Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Takeda: Research Funding; Sellas: Consultancy; Foghorn: Consultancy; Novartis: Consultancy; Merck: Research Funding; Jazz: Research Funding; Immunogen: Honoraria; Gilead: Consultancy, Honoraria, Research Funding. Abedin: Incyte: Research Funding; AltruBio: Research Funding; AbbVie: Consultancy, Honoraria; Actinium Pharmaceutical: Research Funding; Daichii Sankyo: Consultancy, Honoraria; Servier: Consultancy, Honoraria. Wolach: AbbVie, Astellas, Novartis: Speakers Bureau; AbbVie, Astellas, Novartis, Pfizer, Medison, Teva: Consultancy. Vachhani: Cogent Biosciences: Consultancy; Incyte: Consultancy, Speakers Bureau; CTI BioPharma Corp: Consultancy, Speakers Bureau; Daiichi Sankyo: Consultancy; GlaxoSmith Kline: Consultancy; Karyopharm: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Genentech: Consultancy; Servier: Consultancy; Stemline: Consultancy; MorphoSys: Consultancy; LAVA therapeutics: Consultancy; Blueprint Medicines: Consultancy, Speakers Bureau; Amgen: Consultancy; AbbVie: Consultancy. Moshe: Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Stemline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Pollyea: Teva, Karyopharm, Bristol Myers Squibb, and AbbVie.: Research Funding; AbbVie, Bristol Myers Squibb, Syros, Novartis, Beigene, Bergen Bio, Arcellx, Jazz, Genentech, Immunogen, AstraZeneca, Kura, Ryvu, Magenta, Qihan, Zentalis, Medivir, Hibercell, LINK, Daiichi Sankyo, Aptevo, Rigel, Sumitomo, Adicet, Seres, Gilead, OncoVerit: Consultancy. Lai: Genentech: Consultancy; Novartis: Consultancy; Rigel: Consultancy; AbbVie: Consultancy; Astellas: Consultancy; Daiichi: Consultancy; Taiho: Consultancy; Pfizer: Consultancy; BMS: Consultancy; Jazz: Consultancy, Research Funding. LeBlanc: Astellas: Consultancy, Honoraria, Speakers Bureau; Agios: Consultancy, Honoraria, Speakers Bureau; Agilix: Consultancy, Honoraria; Deverra Therapeutics: Research Funding; Duke University: Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Incyte: Honoraria, Speakers Bureau; Dosentrx: Current equity holder in private company; UpToDate: Patents & Royalties; American Cancer Society: Research Funding; Novartis: Consultancy, Honoraria; BlueNote: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria; Jazz Pharmaceuticals: Research Funding; Meter Health: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; CareVive: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Research Funding; Flatiron: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Leukemia and Lymphoma Society: Research Funding; National Institute of Nursing Research/National Institutes of Health: Research Funding; Seattle Genetics: Research Funding; Servier: Consultancy, Honoraria. Xavier: Biegene, Morphosys/Incyte, AbbVie, AstraZeneca, Celgene/BMS, ADC Therapeutics, Blueprint Medicines, Lily/Loxo, Pharmacyclics: Speakers Bureau; Janssen/Pharmacyclics Kite/Gilead, Genentech, AstraZeneca: Honoraria; AbbVie, Acrotec, Blueprint Medicines, Loxo, CTI BioPharma: Consultancy. Nachmias: AbbVie, Medison, Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees. Chen: Rigel: Consultancy; Abbvie: Consultancy. Bui: AbbVie Inc: Current Employment, Current holder of stock options in a privately-held company. Guérin: Analysis Group: Current Employment, Other: I am an employee of Analysis Group, Inc. a consulting company which received funding from Novartis.; Novartis Pharmaceuticals Corporation: Consultancy, Other: I am an employee of Analysis Group, Inc. a consulting company which received funding from Novartis.; AbbVie: Consultancy. Burne: Analysis Group: Current Employment. Ma: Genentech, Inc.: Current Employment, Current equity holder in private company. Grunspan: AbbVie: Current Employment, Current equity holder in publicly-traded company. Frankel: AbbVie: Current Employment, Current equity holder in publicly-traded company. Goldberg: Abbvie: Consultancy, Research Funding; Aprea: Research Funding; Trillium: Research Funding; Prelude: Research Funding; AROG: Research Funding; Pfizer: Research Funding; ADC Therapeutics: Research Funding; Genentech: Consultancy; Daiichi Sankyo: Consultancy, Research Funding; Astellas Pharma: Consultancy; Aptose: Research Funding; DAVA Oncology: Honoraria; Celularity: Research Funding.

*signifies non-member of ASH